Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
10.4 CHF
8.28 B CHF
60.49 B CHF
688.71 M
About ROCHE I
Sector
Industry
CEO
Thomas Schinecker
Website
Headquarters
Basel
Founded
1896
ISIN
CH0012032048
FIGI
BBG00HCYS1N6
Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Roche vs. Novo Nordisk: Who will suffer the Weight Loss?Roche (ticker: ROG.SW) is losing ground on the stock due to the side effects of its new weight loss pill, CT-996, which is still in the testing phase. After a rally that boosted its shares 40% between May and September, the Swiss drugmaker has seen an 11% drop in its shares in September alone, inclu
Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO
Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment.
Management Effectiveness: Roche has been around since 1896
Roche: Ready for 120% Growth?We're trying something with Roche here, where we think that we are currently in Wave (5), having recently completed Wave (4). This assessment is better visualized on the daily chart. Hence, we should maintain the 61.8% level for this Wave 4. Anything below would statistically be too low, while above
Hold it like a rock - Roche, what an opportunity.Hi, 1PERCENT here.
Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma.
There were only 3 pull backs greater than 30% in the history of the stock.
2002 ~ 2003: -45.33%
2006 ~ 2011: -52.40%
2014 ~ 2018: -30.24%
2022 ~ present: -44.89%
It is at the support z
Roche HoldingsThis is one of those companies you can't afford not to look into. Roche is one of the world's largest biotech companies and a global leader in pharmaceuticals and diagnostics. This leading position translates to strong market share, revenue, and profitability. The company operates across various seg
Long Term Weekly Trend holds for nowTrend started in 2012 held during the week. If the price accumulates at the current level and we breakout to the upside, I will watch the marked zones of interest and see how the price reacts.
If we breakout to the down side, I will look for interesting price levels and keep an eye on the trend est
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
CHGCY5317644
Roche Holdings, Inc. 2.607% 13-DEC-2051Yield to maturity
7.23%
Maturity date
Dec 13, 2051
CHGCY4184535
Roche Holdings, Inc. 4.0% 28-NOV-2044Yield to maturity
6.18%
Maturity date
Nov 28, 2044
CHGCY5766486
Roche Holdings, Inc. 5.218% 08-MAR-2054Yield to maturity
6.09%
Maturity date
Mar 8, 2054
CHGCY3666852
Genentech, Inc. 5.25% 15-JUL-2035Yield to maturity
5.48%
Maturity date
Jul 15, 2035
CHGCY5766485
Roche Holdings, Inc. 5.218% 08-MAR-2054Yield to maturity
5.36%
Maturity date
Mar 8, 2054
CHGCY5317198
Roche Holdings, Inc. 2.076% 13-DEC-2031Yield to maturity
5.28%
Maturity date
Dec 13, 2031
CHGCY5766483
Roche Holdings, Inc. 4.985% 08-MAR-2034Yield to maturity
5.19%
Maturity date
Mar 8, 2034
CHGCY5766484
Roche Holdings, Inc. 4.985% 08-MAR-2034Yield to maturity
5.13%
Maturity date
Mar 8, 2034
CHGCY4391962
Roche Holdings, Inc. 7.0% 01-MAR-2039Yield to maturity
5.10%
Maturity date
Mar 1, 2039
CHGCY5766481
Roche Holdings, Inc. 4.909% 08-MAR-2031Yield to maturity
5.09%
Maturity date
Mar 8, 2031
CHGCY5766479
Roche Holdings, Inc. 4.79% 08-MAR-2029Yield to maturity
4.97%
Maturity date
Mar 8, 2029
See all ROG bonds
Curated watchlists where ROG is featured.
Related stocks
Frequently Asked Questions
The current price of ROG is 251.2 CHF — it has increased by 2.63% in the past 24 hours. Watch ROCHE GS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange ROCHE GS stocks are traded under the ticker ROG.
ROG stock has risen by 0.44% compared to the previous week, the month change is a −17.78% fall, over the last year ROCHE GS has showed a 10.76% increase.
We've gathered analysts' opinions on ROCHE GS future price: according to them, ROG price has a max estimate of 448.00 CHF and a min estimate of 230.00 CHF. Watch ROG chart and read a more detailed ROCHE GS stock forecast: see what analysts think of ROCHE GS and suggest that you do with its stocks.
ROG stock is 1.16% volatile and has beta coefficient of 1.15. Track ROCHE GS stock price on the chart and check out the list of the most volatile stocks — is ROCHE GS there?
Today ROCHE GS has the market capitalization of 200.20 B, it has decreased by −15.71% over the last week.
Yes, you can track ROCHE GS financials in yearly and quarterly reports right on TradingView.
ROCHE GS is going to release the next earnings report on Jul 24, 2025. Keep track of upcoming events with our Earnings Calendar.
ROG earnings for the last half-year are 8.57 CHF per share, whereas the estimation was 8.40 CHF, resulting in a 1.98% surprise. The estimated earnings for the next half-year are 10.64 CHF per share. See more details about ROCHE GS earnings.
ROCHE GS revenue for the last half-year amounts to 30.65 B CHF, despite the estimated figure of 30.78 B CHF. In the next half-year revenue is expected to reach 31.51 B CHF.
ROG net income for the last half-year is 2.02 B CHF, while the previous report showed 6.26 B CHF of net income which accounts for −67.74% change. Track more ROCHE GS financial stats to get the full picture.
Yes, ROG dividends are paid annually. The last dividend per share was 9.70 CHF. As of today, Dividend Yield (TTM)% is 3.85%. Tracking ROCHE GS dividends might help you take more informed decisions.
ROCHE GS dividend yield was 3.80% in 2024, and payout ratio reached 93.40%. The year before the numbers were 3.93% and 66.71% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 15, 2025, the company has 103.25 K employees. See our rating of the largest employees — is ROCHE GS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ROCHE GS EBITDA is 21.04 B CHF, and current EBITDA margin is 35.81%. See more stats in ROCHE GS financial statements.
Like other stocks, ROG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ROCHE GS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ROCHE GS technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ROCHE GS stock shows the sell signal. See more of ROCHE GS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.